Tobramycin, a new aminoglycoside antibiotic, was shown to be effective in vitroagainst Pseudomonas, Klebsiella, Staphylococcus aureus, Enterobacter, Proteus mirabilis, indole-positive Proteus, and Eshcherichia coli. It was shown to produce serum and urine concentrations similar to gentamicin when administered intramuscularly. Preliminary animal studies showed this agent to have nephrotoxic and ototoxic effects similar to gentamicin. In our studies, tobramycin was well tolerated and produced only two transient elevations in serum creatinine and no abnormalities in audiograms and vestibular function tests. It was effective in 10 of 12 susceptible infections, including 2 of 4 with Pseudomonas endocarditis. Tobramycin compared favorably with gentamicin and may be superior in treatment of susceptible Pseudomonas infections.
Burch, Keith; Nichols, Richard D.; Quinn, Edward L.; Cox, Frank; Fisher, Evelyn J.; Madhavan, T.; and Pohlod, Donald
"A Clinical Trial of Tobramycin with Pharmacological and Microbiological Studies,"
Henry Ford Hospital Medical Journal
: Vol. 21
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol21/iss3/5